Special Issue

Disruption of Cell Signaling Pathways in Cancer: Prognostic and Treatment Perspectives

Message from the Guest Editors

Cancer is a genetic disease characterized by impaired cell function, uncontrolled cell growth and cell division regardless of environmental signals. Genetic mutations in cancer cells imply the biosynthesis of RNA or proteins with impaired structures and functions, which leads to disruptions in intracellular signaling pathways. Thanks to the use of both modern and traditional research techniques, at least several thousand proteins are now known whose dysfunction is associated with the cancer process. This translates directly or indirectly into the disruption, positive or negative, of the metabolic, signaling, proliferation and other pathways. In this special supplement in the renowned journal *Cancers*, we are interested in obtaining the latest knowledge regarding the analysis of pathway disorders in cancers in the hope of creating modern drugs and improved prognoses for patients

Guest Editors

Dr. Piotr M. Wierzbicki

Department of Histology, Medical University of Gdańsk, 80-214 Gdańsk, Poland

Prof. Dr. Irina Draga-Caruntu

Department of Internal Medicine, 'Grigore T. Popa' University of Medicine, 700115 Iasi, Romania

Deadline for manuscript submissions

closed (30 March 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/189316

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)